Search Results | MSF Science Portal

Journal Article

|

Research

Sinha A, Klebe R, Rekart ML, Alvarez JL, Skrahina A, et al.

2025-02-18 • Clinical Infectious Diseases

BACKGROUND

Only 63% of patients initiating multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment in 2020 were treated successfully. 24-Wee...

Journal Article

|

Research

Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R, et al.

2025-02-01 • Lancet Child and Adolescent Health

BACKGROUND

There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...

Journal Article

|

Research

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A, et al.

2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

Journal Article

|

Research

Khan U, Rich M, Franke M, Lachenal N, Ahmed S, et al.

2024-12-10 • Clinical Infectious Diseases

BACKGROUND

The 2022 WHO guidelines on multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) recommend six months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen ...

Journal Article

|

Letter

Crocker-Buque T, Lachenal N, Narasimooloo C, Abdrasuliev T, Parpieva N, et al.

2024-08-15 • Clinical Infectious Diseases

Journal Article

|

Research

Motta I, Cusinato M, Ludman AJ, Lachenal N, Dodd M, et al.

2024-06-06 • Antimicrobial Agents and Chemotherapy

Regimens for the treatment of rifampicin-resistant tuberculosis currently rely on the use of QT-prolonging agents. Using data from the randomized controlled trial, TB-PRACTECAL, we inves...

Conference Material

|

Slide Presentation

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N, et al.

2024-05-16 • MSF Scientific Day International 2024

Conference Material

|

Abstract

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N, et al.

2024-05-16 • MSF Scientific Day International 2024

INTRODUCTION
Tuberculosis (TB) is a major public health challenge encountered across many Médecins Sans Frontières (MSF) fields. Management of drug-resistant TB is an operational pri...

Journal Article

|

Research

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Abubakirov A, et al.

2024-01-29 • medRxiv

BACKGROUND

Aft...

Journal Article

|

Short Report

Lotia Farrukh I, Lachenal N, Adenov MM, Ahmed SM, Algozhin Y, et al.

2024-01-25 • Clinical Infectious Diseases

Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of ...

Journal Article

|

Protocol

Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M, et al.

2023-11-30 • Trials

BACKGROUND
Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...

Conference Material

|

Slide Presentation

Yatskevich N, Hurevich H, Solodovnikova V, Garsevanidze E, Lachenal N, et al.

2023-06-07 • MSF Scientific Day International 2023

Conference Material

|

Abstract

Yatskevich N, Hurevich H, Solodovnikova V, Garsevanidze E, Lachenal N, et al.

2023-06-07 • MSF Scientific Day International 2023

INTRODUCTION
The total duration of treatment for rifampicin-resistant tuberculosis (RR-TB) in Belarus prior to December 2022 was 18-20 months. The efficacy of treatment with such reg...

Journal Article

|

Research

Huerga H, Khan UT, Bastard M, Mitnick CD, Lachenal N, et al.

2022-10-15 • Clinical Infectious Diseases

BACKGROUND
Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-ben...

Journal Article

|

Research

Hewison CCH, Khan UT, Bastard M, Lachenal N, Coutisson S, et al.

2022-09-15 • Clinical Infectious Diseases

RATIONALE
Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an obstacle to treatment completion.

OBJECTIVES
Evaluate safety of longer MDR/RR-TB...

Journal Article

|

Commentary

Seung KJ, Khan UT, Varaine FFV, Ahmed SM, Bastard M, et al.

2020-10-01 • International Journal of Tuberculosis and Lung Disease

In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major imp...

Journal Article

|

Protocol

Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, et al.

2021-09-25 • Trials

BACKGROUND
Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. W...

Conference Material

|

Abstract

Lachenal N, Hewison CCH, Berry C, Mitnick CD, Ahmed SM, et al.

2022-05-11 • MSF Scientific Days International 2022

INTRODUCTION
Drug-resistant tuberculosis (DR-TB) carries significant morbidity and mortality risk. Care of DR-TB in pregnancy is even more challenging. A recent meta-analysis examini...

Conference Material

|

Video

Lachenal N, Hewison CCH, Berry C, Mitnick CD, Ahmed SM, et al.

2022-06-10 • MSF Scientific Days International 2022

Journal Article

|

Research

Hewison CCH, Bastard M, Khachatryan N, Kotrikadze T, Hayrapetyan A, et al.

2018-07-01 • International Journal of Tuberculosis and Lung Disease

BACKGROUND AND SETTING
Bedaquiline (BDQ) was initially only available through compassionate use programmes.

OBJECTIVE
To assess the effectiveness and safety of multidrug...

Science Portal

The effectiveness and safety of bedaquiline, pretomanid, and linezolid (BPaL)-based regimens for rifampicin-resistant tuberculosis in non-trial settings - A prospective cohort study in Belarus and Uzbekistan

Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country MDR/RR-TB cohort

Pregnancy outcomes in multidrug-resistant tuberculosis in TB-PRACTECAL

How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Nine-month, all-oral regimens for rifampin-resistant tuberculosis

Pregnancy and birth outcomes in patients with multidrug-resistant tuberculosis treated with regimens that include new and repurposed drugs

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus

Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus

Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid and other second-line drugs

Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort

Introducing new and repurposed TB drugs: the endTB experience

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

Pregnancy outcomes in patients undergoing drug-resistant tuberculosis treatment in two closely monitored cohorts

Pregnancy outcomes in patients undergoing drug-resistant tuberculosis treatment in two closely monitored cohorts

Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia